肝癌

1. Wang, Yuanqi et al. “Intratumoral erythroblastic islands restrain anti-tumorimmunity in hepatoblastoma.” Cell reports. Medicine vol. 4,5 (2023): 101044.doi:10.1016/j.xcrm.2023.101044IF: 11.7 Q1

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213871/

2. Li, Qing et al. “PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells.” Nature communications vol. 13,1 7677. 12 Dec. 2022, doi:10.1038/s41467-022-35469-xIF: 14.7 Q1

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744896/

3. Chen, Shuling et al. “Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrences.” Gut vol. 72,6 (2023): 1196-1210. doi:10.1136/gutjnl-2022-328428IF: 23.0 Q1

https://gut.bmj.com/content/72/6/1196.long

4. Zhang, Zhao et al. “Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma.” Oncoimmunology vol. 8,4 e1571388. 7 Feb. 2019, doi:10.1080/2162402X.2019.1571388IF: 6.5 Q1

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422393/

5. Piki, Emilia et al. “ROR1-STAT3 signaling contributes to ovarian cancer intra-tumor heterogeneity.” Cell death discovery vol. 9,1 222. 3 Jul. 2023, doi:10.1038/s41420-023-01527-6IF: 6.1 Q1

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317980/